Ziyu Li

Title: Ziyu Li: Innovator in Antibody Development

Introduction

Ziyu Li is a prominent inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work focuses on addressing autoimmune and autoinflammatory diseases through innovative solutions.

Latest Patents

Ziyu Li holds a patent for a "Humanized anti-IL-1R3 antibody and methods of use." This patent describes an antibody that specifically binds to IL-1R3, featuring an antibody heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2. The patent also includes a pharmaceutical composition that comprises the antibody along with a pharmaceutically acceptable diluent, carrier, or excipient. This antibody is intended for use in treating diseases or disorders in subjects who require such interventions, particularly focusing on autoimmune or autoinflammatory conditions.

Career Highlights

Throughout his career, Ziyu Li has worked with notable companies in the biotechnology sector, including Sanofi Biotechnology and Sanofi. His experience in these organizations has allowed him to refine his expertise in antibody development and therapeutic applications.

Collaborations

Ziyu Li has collaborated with esteemed colleagues such as Christian Lange and Björn Steinmann. These partnerships have contributed to the advancement of his research and the successful development of innovative therapeutic solutions.

Conclusion

Ziyu Li's contributions to the field of biotechnology, particularly through his patent on the humanized anti-IL-1R3 antibody, highlight his role as an innovator in addressing critical health challenges. His work continues to pave the way for advancements in the treatment of autoimmune and autoinflammatory diseases.